Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 26July 2024, including: Narasimhan plays the long game; Merck & Co., Inc.’s RSV contender; Mounjaro’s China approval; the mid-cap rising stars; and AI could add billions in drug revenues.
This and all our other podcasts are available on the Citeline channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "Narasimhan Playing The Long Game At Novartis" - Scrip, 19 July, 2024.)
(Also see "Merck & Co.’s Clesrovimab Could Rival Sanofi/AZ’s Beyfortus In RSV" - Scrip, 23 July, 2024.)
(Also see "Mounjaro Approval Takes Global Obesity Battle To China" - Scrip, 23 July, 2024.)
(Also see "Avidity Is The Mid-Cap Rising Star Of 2024 So Far" - Scrip, 19 July, 2024.)
(Also see "AI/ML Efficiency Gains Could Add Billions To Drug Revenues, Report Finds" - Scrip, 19 July, 2024.)
